NCT04439006View on ClinicalTrials.gov

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions

Aplastic AnemiaHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMonoclonal B-Cell LymphocytosisMonoclonal Gammopathy of Undetermined SignificanceMyelodysplastic SyndromeSymptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

OTHER

Best Practice

Receive usual care

DRUG

Ibrutinib

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Jennifer Woyach

OTHER

NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | Biotech Hunter | Biotech Hunter